Personalized Solriamfetol Therapy Systems with Integrated Technologies
Legal Citation
Summary of the Inventive Concept
The invention integrates solriamfetol therapy with AI, IoT, blockchain, and nano-particle technologies to provide personalized treatment for subjects with impaired renal function, enhancing efficacy and reducing adverse effects.
Background and Problem Solved
The original patent provides optimized dose escalation schemes for solriamfetol therapy in subjects with impaired renal function. However, these schemes have limitations in terms of individualized dosing and real-time monitoring. The new inventive concept addresses these limitations by incorporating advanced technologies to create a more effective and efficient treatment system.
Detailed Description of the Inventive Concept
The inventive concept comprises a wearable device for monitoring renal function, a blockchain-based database for storing patient data, and a machine learning algorithm for adjusting dosage based on individual patient response. The system may also utilize IoT-enabled devices for remote patient monitoring, AI-driven dosing optimization, and blockchain-based data security. Additionally, a novel nano-particle based delivery system can enhance bioavailability and reduce adverse effects. The personalized dosing platform utilizes machine learning to predict patient response, IoT-enabled devices for real-time monitoring, and blockchain-based data storage for secure patient records.
Novelty and Inventive Step
The new claims introduce the synergistic combination of solriamfetol therapy with AI, IoT, blockchain, and nano-particle technologies, which provides a non-obvious and innovative solution for personalized treatment of subjects with impaired renal function. The integration of these technologies enables real-time monitoring, individualized dosing, and enhanced efficacy, distinguishing the inventive concept from the original patent.
Alternative Embodiments and Variations
Alternative embodiments may include the use of different AI algorithms, IoT devices, or blockchain platforms. Variations may include the integration of additional technologies, such as virtual or augmented reality, to enhance patient engagement and treatment outcomes.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the treatment of excessive daytime sleepiness and related disorders. The integration of advanced technologies can provide a competitive advantage in the market, and the personalized treatment approach can lead to improved patient outcomes and increased market share.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical therapeutics, medical device technologies, and digital health systems focused on personalized treatment for patients with renal impairment, requiring expertise in pharmacology, medical device engineering, and digital health technologies
Person of Ordinary Skill (PHOSITA) Profile
A multidisciplinary professional with advanced degrees in pharmaceutical sciences, biomedical engineering, or digital health, possessing knowledge of drug delivery systems, patient monitoring technologies, and data-driven medical interventions
Obviousness Rationale
A PHOSITA would recognize that integrating digital monitoring and AI-driven personalization technologies with existing pharmaceutical treatment protocols represents a predictable and incremental advancement in personalized medicine. The source patent's focus on optimized solriamfetol dosing for renal impairment naturally suggests opportunities for technological augmentation to improve patient outcomes. The proposed technological integrations represent logical extensions of existing medical informatics and precision medicine approaches.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,528 |
|---|---|
| Title | Methods of providing solriamfetol therapy to subjects with impaired renal function |
| Assignee(s) | AXSOME MALTA LTD. |